Nisin

Nisin is a 34-amino acid antimicrobial peptide produced by the bacterium Lactococcus lactis. It is called a 'lantibiotic' (lanthionine-containing antibiotic) because it contains unusual amino acids — lanthionine and methyl-lanthionine — that are created by post-translational modification of the ribosomal peptide. These unusual amino acids form five thioether ring bridges (rings A-E) that give nisin its characteristic polycyclic structure, exceptional stability against heat and proteases, and its unique ability to bind lipid II. First discovered in 1928 by Rogers and Whittier at the USDA, nisin was named in 1947 and has been used in food preservation for over 50 years.

Nisin kills bacteria through two simultaneous mechanisms. First, its N-terminal lanthionine rings (A and B) bind with high affinity to lipid II, the essential membrane-anchored precursor for cell wall synthesis. This alone blocks peptidoglycan construction, similar to vancomycin. Second, the bound lipid II-nisin complex then serves as a docking molecule — nisin's C-terminal region inserts into the membrane using lipid II as an anchor, forming 2 nm pores made of approximately 8 nisin and 4 lipid II molecules. These pores cause rapid ion leakage, ATP loss, and membrane depolarization. This dual pathway means bacteria would need to simultaneously develop resistance to both mechanisms — explaining why significant resistance has not emerged despite 50+ years of use.

Nisin has one of the strongest safety records of any antimicrobial agent. It received FDA GRAS (Generally Recognized As Safe) status in 1988 and is approved as food additive E234 in over 50 countries. The Joint FAO/WHO Expert Committee established an ADI (Acceptable Daily Intake) of 0.13 mg/kg body weight. The oral LD50 in mice is 174 mg/kg — comparable to table salt. Importantly, nisin is rapidly degraded by digestive enzymes (pancreatic proteases) in the human GI tract, meaning it does not accumulate or affect the normal gut microbiome at dietary levels. No adverse effects have been documented across decades of global food use.

Gram-negative bacteria have an additional outer membrane that gram-positive bacteria lack. This outer membrane acts as a physical barrier preventing nisin from reaching its target — lipid II in the cytoplasmic membrane. However, this limitation can be overcome by combining nisin with outer membrane-disrupting agents: EDTA chelates divalent cations that stabilize the outer membrane, and polymyxin directly disrupts the outer membrane lipid structure. Both combinations effectively extend nisin's activity to gram-negative pathogens including E. coli and Pseudomonas.

While nisin is currently approved only for food preservation, there is growing research interest in therapeutic applications. It has shown efficacy in veterinary mastitis treatment (intramammary infusion), topical wound care research, dental applications (anti-plaque, anti-periodontal disease), and even anticancer research (selective cytotoxicity against cancer cells). Its extraordinary safety profile from 50+ years of dietary use provides a strong foundation for clinical development. However, formal human clinical trials for therapeutic indications are still in early stages, and nisin is not currently approved for clinical antimicrobial use.

Both nisin and vancomycin target lipid II, the essential cell wall precursor, but their mechanisms differ significantly. Vancomycin binds the D-Ala-D-Ala terminus of lipid II's peptide chain, blocking transpeptidation. Nisin binds the pyrophosphate region of lipid II using its lanthionine rings, then additionally forms membrane pores — a second killing mechanism that vancomycin lacks. This dual mechanism makes nisin effective against some vancomycin-resistant organisms. However, vancomycin is established for systemic IV therapy while nisin's clinical use is limited to food preservation and topical research applications due to its peptide nature and pharmacokinetic limitations.